AstraZeneca (AZN) Tops Q2 EPS by 17c

Earlier, AstraZeneca (NYSE: AZN) reported Q2 EPS of $1.53, $0.17 better than the analyst estimate of $1.36. Revenue for the quarter came in at $6.66 billion versus the consensus estimate of $6.78 billion.

For earnings history and earnings-related data on AstraZeneca (AZN) click here.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Worthington Steel, Inc. (WS) Misses Q4 EPS by 3c
• Qualcomm unveils Dragonfly CPU, signs Meta as first data center customer
• Raymond James Starts Tonix Pharma (TNXP) at Strong Buy